Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Alanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.59 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.59 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.59 |
| ▸ | GABRP | O00591 | 2/20 | 0.46 |
| ▸ | GABRD | O14764 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.46 |
| ▸ | GABRE | P78334 | 2/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL14677168 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| D-Alanine SCHEMBL1537294 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL186137 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL6534719 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL1675385 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL25189736 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL2083490 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL819876 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL8383645 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL157005 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355729-A1 | MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BARBOUR ROBIN (US) | 2023-11-09 | — | — | US | claimed |
| EP-4213941-A1 | MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | OTHAIR PROTHENA LIMITED (IE) | 2023-07-26 | — | — | EP | claimed |
| CN-116472055-A | Multi-epitope vaccine for treating Alzheimer's disease | 欧萨尔普罗席纳有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-116438191-A | Multi-epitope vaccine for treating Alzheimer's disease | 欧萨尔普罗席纳有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-20230183304-A1 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | PROTHENA BIOSCIENCES INC | 2023-06-15 | — | — | US | claimed |
| EP-4192497-A1 | MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | OTHAIR PROTHENA LIMITED (IE) | 2023-06-14 | — | — | EP | claimed |
| CN-115867304-A | Multi-epitope vaccine for treating alzheimer's disease | 欧萨尔普罗席纳有限公司 | 2023-03-28 | — | — | CN | claimed |
| US-20240216478-A1 | FIBROIN-DERIVED PROTEIN COMPOSITION | SILK TECHNOLOGIES, LTD. (US) | 2024-07-04 | — | — | US | disclosed |
| US-11965005-B2 | Multi-epitope vaccine for the treatment of Alzheimer's disease | OTHAIR PROTHENA LIMITED (IE) | 2024-04-23 | — | — | US | disclosed |
| US-11952406-B2 | Multi-epitope vaccine for the treatment of Alzheimer's disease | OTHAIR PROTHENA LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| US-11945849-B2 | Multi-epitope vaccine for the treatment of Alzheimer's disease | OTHAIR PROTHENA LIMITED (IE) | 2024-04-02 | — | — | US | disclosed |
| WO-2024040132-A2 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2024-02-22 | — | — | WO | disclosed |
| US-11890328-B2 | Fibroin-derived protein composition | SILK TECHNOLOGIES, LTD. (US) | 2024-02-06 | — | — | US | disclosed |
| US-9907836-B2 | Fibroin-derived protein composition | SILK TECHNOLOGIES, LTD. (US) | 2018-03-06 | — | — | US | disclosed |
| WO-2018031973-A1 | SILK-DERIVED PROTEIN FOR TREATING INFLAMMATION | SILK TECHNOLOGIES, LTD. (US) | 2018-02-15 | — | — | WO | disclosed |
| EP-3182985-A1 | FIBROIN-DERIVED PROTEIN COMPOSITION | Silk Technologies Ltd. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20160331815-A1 | FIBROIN-DERIVED PROTEIN COMPOSITION | SILK TECHNOLOGIES, LTD. (US) | 2016-11-17 | — | — | US | disclosed |
| US-9394355-B2 | Fibroin-derived protein composition | SILK TECHNOLOGIES, LTD. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160096878-A1 | FIBROIN-DERIVED PROTEIN COMPOSITION | SILK TECHNOLOGIES, LTD. (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2016029034-A1 | FIBROIN-DERIVED PROTEIN COMPOSITION | SILK TECHNOLOGIES, LTD. (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331815-A1 | FIBROIN-DERIVED PROTEIN COMPOSITION | FIBP, SFXN1, SDAD1 | GLRA1 3592/4885SLC6A9 2806/4885OR51E2 1820/4885 |
| US-20160096878-A1 | FIBROIN-DERIVED PROTEIN COMPOSITION | FIBP, SFXN1, SDAD1 | GLRA1 3592/4885SLC6A9 2806/4885OR51E2 1820/4885 |
| US-20240216478-A1 | FIBROIN-DERIVED PROTEIN COMPOSITION | FIBP, SDAD1, PDAP1 | GLRA1 2733/4885SLC6A9 2926/4885OR51E2 1820/4885 |
| US-11890328-B2 | Fibroin-derived protein composition | FIBP, SDAD1, PDAP1 | GLRA1 2733/4885SLC6A9 2926/4885OR51E2 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.